Skip to content
Back to meeting Original
METCrusaders· @metcrusaders · X·· 1 day agoScore45
Body

Promising news about osimertinib + savolitinib for EGFR-mutated NSCLC with MET overexpression or MET amplification #lscm #ESMO26

5 views · 0 likes · 0 reposts · 0 replies

引用@
Simultaneous publication @NEJM of #ESMO26 presentation from Dr. Shun Lu. Osimertinib + savolitinib superior to chemo in EGFR+ NSCLC post osimertinib with MET overexpression and/or amp: 338 randomized / 1746 screened: PFS 7.6 vs 5.4m, HR 0.55, OS HR 0.68 https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
在 X 查看被引用的帖子

Source: METCrusaders · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.